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Multidrug-resistant Klebsiella pneumoniae and Escher-
ichia coli isolates harboring New Delhi metallo-β-lactamase 
(NDM-1) were isolated from a patient who had returned to 
Canada from India. The NDM-1 gene was found on closely 
related incompatibility group A/C type plasmids. The occur-
rence of NDM-1 in North America is a major public health 
concern.
C
arbapenem-hydrolyzing β-lactamases, i.e., carbapen-
emases, in bacterial clinical isolates are an increasing 
concern because they often also confer resistance to most 
other β-lactam antimicrobial agents. Among Enterobacte-
riaceae, carbapenemases are mainly found in the Ambler 
class A penicillinase or class B metallo-enzyme groups. 
VIM and IMP are the most frequently acquired class B en-
zymes and are commonly found in southern Europe and the 
Far East, rarely in North America. Klebsiella pneumoniae 
carbapenemase (KPC) class A has been found worldwide, 
although it emerged in the eastern United States in the mid 
1990s and subsequently has successfully established itself 
in multiple states (1). 
Recently, a new class B enzyme, New Delhi metallo-
β-lactamase (NDM-1), was characterized from a K. pneu-
moniae isolate from Sweden; the bacteria seem to have 
been imported from India (2). Enterobacteriaceae isolates 
harboring NDM-1 have now been found in multiple areas 
of India and Pakistan and in the United Kingdom (3–5); 
such isolates were recently reported from 3 US states (6). 
In Canada, carbapenemase-harboring isolates are rare, re-
ported only for a small outbreak of clonal Pseudomonas 
aeruginosa isolates harboring IMP-7, P. aeruginosa iso-
lates harboring VIM-2, a Serratia marcescens isolate har-
boring a SME-2 class A β-lactamase, and 3 isolates of K. 
pneumoniae harboring KPC-3 (7–10). We characterized 
NDM-harboring clinical isolates from a patient who had 
recently traveled to India.
The Study 
A 76-year-old woman returned to Vancouver, British 
Columbia, Canada, in early 2010 after spending 3.5 months 
in northern India. Before her trip, she had been in good 
health. In India, persistent nonbloody diarrhea developed, 
for which she did not seek medical attention. One month 
later, she was treated in the hospital for hypertension and 
congestive heart failure. She was discharged 3 days after 
admission but readmitted 3 days later because of ongoing 
diarrhea and decreased consciousness. Unspeciﬁ  ed  en-
cephalitis and a urinary tract infection were diagnosed, but 
despite antibacterial drug therapy, her neurologic status did 
not improve over the next 3 weeks. She was discharged 
from the hospital in India and transferred to Canada.
When she arrived at the hospital in Vancouver on Feb-
ruary 14, 2010, her vital signs reﬂ  ected distributive shock: 
temperature 38.3°C, blood pressure 100/80 mm Hg, and 
heart rate 126 beats/minute. Sepsis was suspected and she 
was given imipenem and vancomycin. Within 24 hours, her 
level of consciousness had deteriorated, and she was admit-
ted to the intensive care unit and intubated for airway pro-
tection. Blood cultures were negative, but urine culture (>1 
× 108 CFU/mL) grew highly drug-resistant K. pneumoniae 
N10–0469 (February 15, 2010) with intermediate resistance 
to chloramphenicol and susceptibility to colistin. The urine 
was packed with leukocytes, and no other source for sep-
sis was found. A perirectal sample, screened for resistant 
gram-negative rods, grew K. pneumoniae N10–0506 and E. 
coli N10–0505 (February 16, 2010). A stool specimen was 
negative for ova and parasites but positive for Clostridium 
difﬁ  cile toxin.
The patient was given vancomycin and metronidazole 
for the C. difﬁ  cile infection and colistin for the K. pneu-
moniae infection. Treatment with colistin was discontinued 
shortly after its initiation because of the onset of renal com-
plications; treatment with chloramphenicol was successful. 
Test results for infectious causes of encephalitis (e.g., ma-
laria smears, cerebrospinal ﬂ  uid culture for bacteria, and 
staining for acid-fast bacteria and fungi) were negative, as 
were test results for cryptococcal antigen, herpes simplex 
viruses 1 and 2, Japanese encephalitis virus, and rabies 
virus. Results of computed tomographic scans, magnetic 
resonance imaging of the head, and an electroencephalo-
gram were suggestive of global metabolic encephalopathy. 
Neurologic symptoms did not improve, despite the suc-
cessful treatment of the urinary tract infection. Subsequent-
ly, E. coli N10–0705 isolate with an extended-spectrum 
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9, 2010, for which the patient was treated with imipenem.
Ventilator and vasopressor support were eventually 
removed, and the patient was transferred to the general 
medicine ward. Several days later, her condition worsened 
and she died; the ﬁ  nal diagnosis was toxic metabolic leu-
koencephalopathy, probably related to sepsis. The patient’s 
family refused to allow an autopsy.
Macrorestriction analysis of the 4 isolates showed 
that K. pneumoniae N10–0469 and N10–0506 were close-
ly related, although E. coli N10–0505 and N10–0705 were 
not (Figure 1). All 4 isolates contained multiple plasmids 
(data not shown). β-lactamase PCR and sequencing were 
conducted (primers listed in Table 1). K. pneumoniae 
N10–0469 and N10–0506 harbored the genes for SHV-1, 
CTX-M-15, OXA-1, CMY-6, and NDM-1; E. coli N10–
0505 harbored TEM-1, CTX-M-15, CMY-6, and NDM-1; 
and  E. coli N10–0705 harbored TEM-1, CTX-M-15, 
OXA-1, and CMY-42. The ﬁ  rst characterized isolate from 
Sweden that harbored blaNDM-1 also harbored CMY-4, a 
Trp221Arg variant of the widespread CMY-2 β-lactamase 
(3). CMY-6 is a Trp221Leu variant of CMY-2 (GenBank 
accession no. AJ011293). CMY-42 is a Val231Ser variant 
of CMY-2.
Antimicrobial drug susceptibility testing by Sensititer 
panels ESB1F and CMV1AGNF (Trek Diagnostic Sys-
tems, Cleveland, OH, USA) found that all 4 isolates were 
multidrug resistant and that 3 of the 4 isolates, not E. coli 
N10–0705, were nonsusceptible to carbapenems (Table 
2). Nonsusceptibility to carbapenems was also shown by 
Etest (bioMérieux, St. Laurent, Quebec, Canada) and disk 
diffusion (Table 2). K. pneumoniae N10–0469 and E. coli 
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Figure 1. Macrorestriction analysis (XbaI) by pulsed-ﬁ  eld  gel 
electrophoresis of Klebsiella pneumoniae N100469 (lane 1), 
K. pneumoniae N10–0506 (lane 2), Escherichia coli N10–0505 
(lane 3), E. coli N10–0705 (lane 4), Salmonella enterica serovar 
Branderup molecular mass marker (XbaI) (lanes SB).
Table 1. Primers used in study of New Delhi metallo-ȕ-lactamase in Klebsiella pneumoniae and Escherichia coli, Canada, 2010 
Name Sequence,  5ƍ o 3ƍ*  Product size, bp 
SHV-UP CGCCGGGTTATTCTTATTTGTCGC  1,016 
SHV-LO TCTTTCCGATGCCGCCGCCAGTCA 
TEM-G TTGCTCACCCAGAAACGCTGGTG  708 
TEM-H TACGATACGGGAGGGCTTACC 
CTX-U1 ATGTGCAGYACCAGTAARGTKATGGC  593 
CTX-U2 TGGGTRAARTARGTSACCAGAAYCAGCGG 
OXA1-F CGCAAATGGCACCAGATTCAAC  464 
OXA1-R TCCTGCACCAGTTTTCCCATACAG 
CMY2-A TGATGCAGGAGCAGGCTATTCC  323 
CMY2-B CTAACGTCATCGGGGATCTGC 
KPC1 ATGTCACTGTATCGCCGTC  863 
KPC2 AATCCCTCGAGCGCGAGT 
VIM1 GTTTGGTCGCATATCGCAAC  382 
VIM2 AATGCGCAGCACCAGGATAGAA 
IMP1 CCWGATTTAAAAATYGARAAGCTTG  522 
IMP2 TGGCCAHGCTTCWAHATTTGCRTC 
NDM-F GGTGCATGCCCGGTGAAATC  660 
NDM-R ATGCTGGCCTTGGGGAACG 
NDM-A CACCTCATGTTTGAATTCGCC  984 
NDM-B CTCTGTCACATCGAAATCGC 
*H is A, C, or T; K is G or T; R is A or G; S is G or C; and W is A or T. NDM-1 Metallo-β-Lactamase, Canada
N10–0505 were susceptible to colistin, polymixin B, and 
tigecycline.
Multilocus sequence typing of K. pneumoniae N10–
0469 showed that it was sequence type (ST) 16 (11). The 
ﬁ  rst characterized strain of K. pneumoniae that harbored 
NDM-1 was ST14, unrelated to ST16 (3). Mutilocus se-
quence typing of E. coli N10–0505 showed it to be ST405 
(12). The worldwide spread of blaCTX-M-15 has been partly 
attributed to 2 epidemic strains, ST131 and ST405 (13). 
E. coli DH10B harboring NDM-1 plasmids was 
obtained by electrotransformation with whole plasmid 
DNA with selection on 0.25 μg/mL meropenem. Aga-
rose gel analysis of transformants showed that they car-
ried only a single, large plasmid. PCR and sequencing 
showed that CMY-6 and NDM-1 were located on an 
≈102-kb plasmid (pNDM-Kp10469), originating from 
K. pneumoniae N10–0469, and on an ≈129-kb plasmid 
(pNDM-Ec10505), originating from E. coli N10–0505 
(Figure 2). Incompatibility (Inc) group PCR (14) and 
ﬁ  ngerprinting (15) showed that both plasmids were re-
lated Inc A/C types, indicating possible horizontal trans-
fer in vivo (Figure 2).
Transformant susceptibility to aztreonam is consistent 
with the inability of class B enzymes to efﬁ  ciently hydro-
lyze this drug. Transformants exhibited lower carbapen-
em MICs than did clinical isolates, likely reﬂ  ecting total 
β-lactamase content and additional resistance mechanisms 
such as porin mutations in the clinical isolates (Table 2). 
The recent emergence of blaNDM-1 in India has been linked 
to its spread on the Inc A/C-type, IncF1/FII-type, or un-
known plasmid types (3). Analysis for class 1 integron cas-
settes found that both plasmids contained a 0.8-kb cassette 
that coded for aac(6′)-Ib–type aminoglycoside 6′-N-acetyl 
transferase. PCR for the ISCR1 element associated with 
some class 1 integrons was negative. Plasmids harboring 
NDM-1 plasmids were successfully transferred by conjuga-
tion from K. pneumoniae N10–0469 and E. coli N10–0505 
to recipient strain E. coli RG192 (rifampin resistant). 
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Table 2. Antimicrobial drug susceptibilities of the isolates from study of New Delhi metallo-ȕ-lactamase in Klebsiella pneumoniae and 




E. coli DH10B 
(pNDM-Kp10469) E. coli N10–0505 
E. coli DH10B 
(pNDM-Ec10505)  E. coli DH10B 
Broth microdilution (MIC, Pg/mL)         
 Amoxicillin/clavulanic  acid  >32 >32 32 >32  4
 Piercillin/tazobactam  >64 >64 >64 >64  <4
 Ampicillin  >16 >16 >16 >16  2
 Cefazolin  >16 >16 >16 >16  <8
 Cefotaxime  >64 >64 >64 >64  <0.25
 Cefotaxime/clavulanic  acid  >64 >64 >64 >64  <0.12
 Ceftazidime  >128 >128 >128 >128  <0.25
 Ceftazidime/clavulanic  acid  >128 >128 >128 >128  0.25
 Cefepime  >16 16 >16 16  <1
 Cefoxitin  >64 >64 >64 >64  8
 Imipenem  >16 4 2 2  <0.5
 Meropenem  >8 2 8 2  <1
 Chloramphenicol  16 4 32 4  <2
 Tetracycline  >32 d4  32 d4  <4
 Amikacin  >64 >64 >64 >64  2
 Gentamicin  >16 >16 >16 >16  <0.25
 Ciprofloxacin  >2 <0.015 >2 <0.015  <0.015
 Trimethoprim/sulfamethoxazole  >4 <0.12 >4 <0.12  <0.12
Etest (MIC, Pg/mL)         
 Aztreonam  >256 4 >256 4  0.094
 Imipenem  >32 4 >32 4  0.19
 Meropenem  >32 8 32 6  0.032
 Ertapenem  >32 16 >32 16  0.008
 Colistin  0.38 ND 0.38 ND  ND
 Polymyxin  B  0.19 ND 0.25 ND  ND
 Tigecycline  1.5 ND 0.125 ND  ND
Disk diffusion (zone diameter, mm)         
 Imipenem  6  14 11 13  33
 Meropenem  6  15 10 14  35
 Ertapenem  6  13 6 13  35
*NDM, New Delhi metallo-ȕ-lactamase; ND, not done. Conclusions 
North America has thus far escaped the widespread es-
tablishment of metallo-β-lactamase–harboring organisms. 
Therefore, the emergence of blaNDM-1-harboring Enterobac-
teriaceae in North America is of concern because such 
isolates exhibit resistance to drugs commonly used to treat 
gram-negative infections (β-lactams, ﬂ  uoroquinolones, and 
aminoglycosides) and have shown a propensity to spread 
rapidly (4–6). 
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Figure 2. BglII restriction digests of New Delhi metallo-β-lactamase 
(pNDM)–Kp10469 (lane 1) and pNDM-Ec10505 (lane 2). MW, 1-kb 
extension ladder molecular mass marker (Invitrogen, Carlsbad, 
CA, USA). Sizes (kb) are indicated for some bands.
Use of trade names is for identiﬁ  cation only and does not 
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